‘Baby brain' is real. 3 things to know about what's happening to your brain
Pregnancy is one of the three Ps (puberty, pregnancy and perimenopause), a time when a person's brain undergoes physical changes due to hormones. d3sign//File via CNN Newsource
Science has pretty well established that the brain isn't static; it changes and adapts throughout our lives in response to life events in a process called neuroplasticity.
Researchers are discovering this is especially true of female brains, which get remodeled significantly during the three Ps: puberty (as do the brains of adolescent males), pregnancy and perimenopause.
All three transitions are a frequent butt of pop-culture jokes: the sulky, risk-taking teenager who only wants to be with friends; the scattered mom-to-be who leaves her cell phone in the fridge and can't remember where she parked the car; and the hormonal middle-aged woman who can't focus and spontaneously combusts with hot flashes.
But far from being laughable, these behavioral stereotypes are the external manifestations of big internal shifts, many of them linked to the effects of fluctuating hormones on the brain.
Cognitive neuroscientist Laura Pritschet, a postdoctoral fellow in the department of psychiatry at the University of Pennsylvania, is fascinated by how female hormones, including estrogen and progesterone, affect the brain's organization and functioning.
'The reason I chose that field is because I was a budding neuroscientist as an undergrad, interested in brain networks and obsessing over how intricate everything was in the brain to simply allow us to have a personality or remember things,' Pritschet told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently, on his podcast Chasing Life.
'At the same time in my personal life, I was surrounded by menopausal women who were talking about their cognitive complaints and their attention issues,' she said. 'I thought we've got to connect these two together and understand this more.'
Pritschet even volunteered as a 'guinea pig' during graduate school, having her brain scanned and blood drawn for 30 days, across two complete reproductive cycles (both on and off birth control pills), to begin to answer the question of how the day-to-day fluctuations in hormones relate to the day-to-day changes in the brain.
Around this time, other researchers were studying what happens in the brain during pregnancy, Pritschet said, looking at the brain before and after gestation. They found many changes, but because the studies took a snapshot approach, many questions were left unanswered.
'If there's a 3 to 5% decrease in total gray matter volume, when is that occurring (during pregnancy), and how is it occurring?' Pritschet asked. 'We're missing huge gaps in what we call this metamorphosis.
'We know that the 40-week gestational window leads to these body adaptations to support the development of the fetus: We have increased plasma volume, immune function change, metabolic rate, oxygen consumption,' she said. 'What does this trajectory look like over gestation?'
To find out, Pritschet and her team tracked the brain changes in one woman, using MRI and blood draws, from pre-conception and fertility treatment throughout her pregnancy to two years postpartum. Their findings were published in the journal Nature Neuroscience in September.
'We saw this reduction in gray matter volume pretty much across the whole brain,' Pritschet explained. 'We saw increased white matter microstructure and ventricle size.' (Quick anatomy lesson: The brain is made up of gray and white matter. Gray matter is where most of the brain's thinking and processing takes place. White matter helps connect the different brain areas, allowing them to communicate with one another.)
'The inflection point was birth,' Pritschet said. 'We saw that those reductions persisted into postpartum, with slight recovery, meaning that certain areas of the brain showed this rise in gray matter volume in early postpartum. Others did not.'
Pritschet said this 'choreographed dance between major features of our brain' is in one respect a physical adaptation to the increased blood flow and swelling that comes with pregnancy.
Additionally, the changes may also be a preparation for the next stage: parenting.
'It's a fine-tuning of circuits,' she explained. 'We know that pregnancy is the lead-up to this time in your life where there's a lot of behavioral adaptation that has to occur, and new cognitive demands, and a new cognitive load.
'And so the idea here is that there is this pruning or this delicate rewiring to make certain networks or to make communication in the brain more efficient to meet the demands that are going to have to occur,' Pritschet said.
This theory is supported by earlier work. 'The first pinnacle papers that came out looking at neuroanatomy in human women from preconception to postpartum found that degree of change in gray matter volume — that sort of reduction — correlated with various … maternal behaviors (such as bonding). Again, that's all correlation,' she said.
'That's an area we need to do a lot more research on, and it needs a lot of context,' she said. 'But you can expect that if there's fine-tuning in these circuits that underlie cognitive or behavioral process, that the more fine-tuning it undergoes, the better performance you're going to have. That's the idea — but it's so much more complicated than that.'
What happens to the brain during pregnancy? Pritschet offers these three insights.
The only constant is change
The body is the outward sign of a lot of inner upheaval.
'Pregnancy is a transformative time in a person's life where the body undergoes rapid physiological adaptations to prepare for motherhood,' Pritschet said via email. 'But pregnancy doesn't just transform the body — it also triggers profound change to the brain and reflects another critical period of brain development.'
She called this remodeling an often-overlooked period of brain development that takes place well into a woman's adulthood.
How alarmed should women be?
Less gray matter may not sound very positive, but it happens for a reason.
'Despite what one might think, these reductions are not a bad thing, and in fact, are to be expected,' Pritschet said, noting that some of the losses are eventually regained. 'This change could indicate a 'fine-tuning' of brain circuits, not unlike what happens to all young adults as they transition through puberty and their brain becomes more specialized.'
These changes could also be a response to the high physiological demands of pregnancy itself, she said, 'showcasing just how adaptive the brain can be.'
These changes could affect future health and behavior
Mapping these changes could open the door to understanding an array of other neurological and behavioral outcomes including postpartum depression, headaches, migraines, epilepsy, stroke and parental behavior.
'The neuroanatomical changes that unfold during (pregnancy) have broad implications for understanding vulnerability to mental health disorders … and individual differences in parental behavior,' said Pritschet.
It may even provide critical insight into how the brain changes over a lifespan, she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
an hour ago
- Globe and Mail
Multiple Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Multiple sclerosis Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Sclerosis Treatment Landscape. Click here to read more @ Multiple Sclerosis Pipeline Outlook Key Takeaways from the Multiple Sclerosis Pipeline Report In May 2025, Novartis Pharmaceuticals announced a Phase IV study in which breastfeeding mothers treated with ofatumumab and their babies are taking part for up to 1 year. The study consists of a Core Part and a Safety Follow-up Part. The Core Part includes a Screening period and a Sampling period. During the Screening period (up to 4 weeks), the study doctor will assess if mothers can join the study. The Sampling period, during which milk samples and a blood sample will be collected, will last for up to 12 weeks. The Safety Follow-up Part will last for about 9 months, to follow up on health and safety of mothers and their babies. In May 2025, Hoffmann-La Roche announced a study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab. In May 2025, Eli Lilly and Company conducted a study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up. In May 2025, Biocad announced a clinical study is to assess the long-term efficacy and safety of BCD-132 (divozilimab) in patients with multiple sclerosis who previously participaded in BCD-132-2 and BCD-132-4/MIRANTIBUS studies. In May 2025, Sanofi conducted a study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. In May 2025, Biogen organized a study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS. DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment. The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Stay informed about the cutting-edge advancements in Multiple Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Multiple Sclerosis Clinical Trials Assessment Multiple sclerosis Emerging Drugs Profile IMU-838: Immunic Therapeutics Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties. BIIB091: Biogen BIIB091 selectively inhibits Burton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis. IMCY-0141: ImCyse IMCY-0141 is the Company's second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis. NeuroVax: Immune Response BioPharma NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Studies suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin. NeuroVax is a Once a Month Dosing injection, safe, tolerable, enhances FOXP3+ Tregs & Regulates Pathogenic T Cells in MS Patients, a first in class disease modifying Multiple Sclerosis Vaccine. NeuroVax IR has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides combined in it correspond to one or more TCR gene families which are over expressed in 90% of MS patients. The Multiple Sclerosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment. Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different Multiple Sclerosis mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market Learn more about Multiple Sclerosis Drugs opportunities in our groundbreaking Multiple Sclerosis research and development projects @ Multiple Sclerosis Unmet Needs Multiple Sclerosis Companies Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Multiple Sclerosis Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Multiple Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives Scope of the Multiple Sclerosis Pipeline Report Coverage- Global Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Multiple Sclerosis Pipeline on our website @ Multiple Sclerosis Emerging Drugs and Companies Table of Content Introduction Executive Summary Multiple sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Multiple sclerosis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) IMU-838: Immunic Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) BIIB091: Biogen Drug profiles in the detailed report….. Early Stage Products (Phase I) NeuroVax: Immune Response BioPharma Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Multiple sclerosis Key Companies Multiple sclerosis Key Products Multiple sclerosis- Unmet Needs Multiple sclerosis- Market Drivers and Barriers Multiple sclerosis- Future Perspectives and Conclusion Multiple sclerosis Analyst Views Multiple sclerosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


Globe and Mail
3 hours ago
- Globe and Mail
Major Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment
DelveInsight's 'Major Depressive Disorder Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Major Depressive Disorder Pipeline. Dive into DelveInsight's comprehensive report today! @ Major Depressive Disorder Pipeline Outlook Key Takeaways from the Major Depressive Disorder Pipeline Report In May 2025, Biohaven Therapeutics Ltd announced a study to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD). In May 2025, Neurocrine Biosciences conducted a study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression. In May 2025, Neumora Therapeutics, Inc. organized a study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501). In May 2025, Otsuka Pharmaceutical Development & Commercialization, Inc. announced a phase 2 study parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD). In May 2025, Janssen Research & Development LLC announced a study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD). DelveInsight's Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment. The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others. Promising Major Depressive Disorder Pipeline Therapies such as NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others. Stay ahead with the most recent pipeline outlook for Major Depressive Disorder. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Major Depressive Disorder Medication Major Depressive Disorder Emerging Drugs Profile SAGE-217: Sage Therapeutics SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD). REL-1017: Relmada Therapeutics Inc. REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD. Seltorexant: Minerva Sciences Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development. SP-624: Sirtsei Pharmaceuticals, Inc. SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc. SPL026: Small Pharma SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world's first DMT clinical trial for depression, in collaboration with Imperial College London. PDC-1421: BioLite Inc. PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development. The Major Depressive Disorder Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Major Depressive Disorder with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Medication. Major Depressive Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Major Depressive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Major Depressive Disorder market Explore groundbreaking therapies and clinical trials in the Major Depressive Disorder Medication. Access DelveInsight's detailed report now! @ New Major Depressive Disorder Drugs Major Depressive Disorder Companies GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others. Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Subcutaneous Intravenous Intramuscular Major Depressive Disorder Products have been categorized under various Molecule types such as Bispecific Antibody Peptides Small molecule Gene therapy Unveil the future of Major Depressive Disorder Medication. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Major Depressive Disorder Market Drivers and Barriers Scope of the Major Depressive Disorder Pipeline Report Coverage- Global Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others. Major Depressive Disorder Pipeline Therapies- NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others. Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Major Depressive Disorder Medication and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Major Depressive Disorder Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Major Depressive Disorder: Overview Pipeline Therapeutics Therapeutic Assessment Major Depressive Disorder – DelveInsight's Analytical Perspective Late Stage Products (Preregistration) SAGE-217: Sage Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) SP-624: Sirtsei Pharmaceuticals, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I/II) SPL026: Small Pharma Drug profiles in the detailed report….. Preclinical Stage Products Drug Name: Company name Drug profiles in the detailed report….. Inactive Products Major Depressive Disorder Key Companies Major Depressive Disorder Key Products Major Depressive Disorder- Unmet Needs Major Depressive Disorder- Market Drivers and Barriers Major Depressive Disorder- Future Perspectives and Conclusion Major Depressive Disorder Analyst Views Major Depressive Disorder Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


CTV News
6 hours ago
- CTV News
Smoke prompts special air quality statement east of Winnipeg
Air quality expert Jed Kaplan explains the concerns over wildfire smoke, who is most at risk and how we can protect ourselves.